<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03676803</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#17-000617</org_study_id>
    <nct_id>NCT03676803</nct_id>
  </id_info>
  <brief_title>Effect of Spice Consumption on the Microbiome</brief_title>
  <official_title>Effect of Spice Consumption on the Microbiome in Healthy Subjects: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several human intervention studies have also been performed that demonstrated beneficial
      effects of high polyphenol fruits and vegetable on the intestinal microbiome. No information
      is available about the effect of spice consumption on the gut microbiome.

      This proposed pilot study will assess the ability of daily consumption of 5 grams of mixed
      spices to alter the gut microbiome composition compared to placebo in a free-living
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blinded, placebo controlled design. Thirty-one subjects
      will be randomized to consume either 5 grams of mixed spice or matched placebo for 2 weeks in
      random sequence. At baseline and week 2, fasting blood, urine and stool will be collected. In
      addition body weight and composition will be determined and questionnaires and 3-day food
      record will be completed. Stool samples will be collected for sequencing of bacterial DNA to
      determine changes in the microbiota. The objective of the proposed pilot study is to
      determine whether intake of spice per day will alter the intestinal microflora leading to an
      increase in formation of short chain fatty acids.

      Subjects will be assigned an enrollment number after signing the informed consent form
      approved by the UCLA Medical Internal Review Board. Eligible subjects will be enrolled into
      the study upon completion of screening evaluations, which include a physical exam, complete
      medical history, and blood drawing.

      This study will be conducted in healthy free-living subjects (18-65 years). Subjects consume
      5 gram mixed spices or placebo capsules daily for 2 weeks. Subjects will be instructed to eat
      a beige diet (low fiber&lt;10g and low polyphenols &lt;3 servings of polyphenol rich
      fruit/vegetables per day) during the entire study period. Participants will meet with the
      dietitian for instructions on eating a beige diet and will be instructed to follow the diet
      during the entirety of the study.

      All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano,
      1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of
      5.0g spice mixture - identical to herbs and spices sold in grocery stores for human
      consumption. There are no known safety issues with any of the ingredients.

      Placebo capsules will contain maltodextrin equivalent to mixed spice blend.

      Body weight will be measured on an uncarpeted surface on a scale (Detecto-Medic;
      Detecto-Scales; Brooklyn, NY) while wearing no shoes and after an overnight fast. Height is
      measured without shoes with a stadiometer (Detecto-Medic; Detecto-Scales; Brooklyn, NY) and
      recorded to the nearest 0.1 cm. Body composition will be measured using the Tanita-BC418
      body-fat analyzer (Tanita Corp., Tokyo, Japan).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Actual">May 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Microbial Phylum Abundance (% of Total) Between Spice and Placebo</measure>
    <time_frame>2-weeks</time_frame>
    <description>Change in microbial phylum abundance (% of total) between spice and placebo after two week intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Short-chain Fatty Acids (SCFAs) at 2 Weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change from baseline in total SCFAs including acetate, propionate, butyrate and valerate in response to mixed-spice intervention for 2 weeks. SCFAs were measured in dry fecal sample determined as micromole per gram of dry weight.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Microbiota</condition>
  <arm_group>
    <arm_group_label>Mixed spices intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy participants consume a capsule containing 5 g of mixed spices at culinary dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>healthy participants consume placebo capsule containing 5 g of maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mixed spices</intervention_name>
    <description>All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.</description>
    <arm_group_label>Mixed spices intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo capsule containing 5 g of maltodextrin</intervention_name>
    <description>placebo capsule containing 5 g of maltodextrin</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy human adults age 18-65 years old

          -  Typically consume low fiber/polyphenol diet (beige diet)-

        Exclusion Criteria:

          -  Eating a high fiber/polyphenol diet or taking any medication or dietary supplement
             which interfere with the absorption of polyphenols.

          -  History of gastrointestinal surgery, diabetes mellitus, or other serious medical
             condition, such as chronic hepatic or renal disease, bleeding disorder, congestive
             heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery
             bypass graft, angioplasty within 6 months prior to screening, current diagnosis of
             uncontrolled hypertension (defined as systolic BP &gt;160mmHg, diastolic BP &gt; 95mmHg),
             active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or
             endocrine diseases (except thyroid disease requiring medication) as indicated by
             medical history or routine physical examination.

          -  Pregnant or breastfeeding

          -  Currently uses tobacco products.

          -  Is unable or unwilling to comply with the study protocol.

          -  Frequently using prebiotics, probiotics, yogurt, and/or any fiber supplements

          -  Allergy or sensitivity to spices. Subjects will be excluded if there is a prior
             history of such sensitivity. Since these foods are commonly eaten and allergies are
             rare, subjects should be aware of this sensitivity prior to entering the study. To
             determine this, a positive history of spices ingestion without incident will be
             requested. In addition, any subject with a history of allergy or anaphylaxis of any
             kind will be excluded

          -  Taking antibiotics or laxatives within the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoping Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Nutrition, UCLA David Geffen School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Center for Human Nutrition, 900 Veteran Ave.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <results_first_submitted>October 15, 2019</results_first_submitted>
  <results_first_submitted_qc>November 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2019</results_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Zhaoping Li</investigator_full_name>
    <investigator_title>Professor and Chief</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03676803/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03676803/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Interested participants who responded to the approved flyers called the research site and a coordinate conducted a screening by utilizing a screening script. Initial eligibility was determined by a telephone conversation. Eligible subjects were scheduled for a screen visit.</recruitment_details>
      <pre_assignment_details>After one week run-in period, thirty-one participants were enrolled and randomized into mixed-spices intervention group and placebo group. All have completed the two-week intervention study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mixed Spices Intervention Group</title>
          <description>Healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
Mixed spice capsules contain 1 g cinnamon, 1.5 g oregano, 1.5 g ginger, 0.85g black pepper and 0.15g cayenne pepper for a total of 5.0 g. They are identical to herbs and spices sold in grocery stores for human consumption.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Healthy participants consume placebo capsule containing 5 g of maltodextrin
Placebo capsules contain 5 g maltodextrin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mixed Spices Intervention Group</title>
          <description>Healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
Mixed spice capsules contain 1 g cinnamon, 1.5 g oregano, 1.5 g ginger, 0.85g black pepper and 0.15g cayenne pepper for a total of 5.0 g.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Healthy participants consume placebo capsule containing 5 g of maltodextrin
Placebo capsules contain 5 g maltodextrin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.8" spread="12.2"/>
                    <measurement group_id="B2" value="35.6" spread="13.7"/>
                    <measurement group_id="B3" value="35.2" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="6.8"/>
                    <measurement group_id="B2" value="26.7" spread="4.4"/>
                    <measurement group_id="B3" value="27.5" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Microbial Phylum Abundance (% of Total) Between Spice and Placebo</title>
        <description>Change in microbial phylum abundance (% of total) between spice and placebo after two week intervention</description>
        <time_frame>2-weeks</time_frame>
        <population>Data from one participant from spice group and one from placebo group were excluded due to non-compliance with the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Mixed Spices Intervention Group</title>
            <description>Healthy participants consume a capsule containing 5 g of mixed spices daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Healthy participants consumed placebo capsules daily for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Microbial Phylum Abundance (% of Total) Between Spice and Placebo</title>
          <description>Change in microbial phylum abundance (% of total) between spice and placebo after two week intervention</description>
          <population>Data from one participant from spice group and one from placebo group were excluded due to non-compliance with the protocol.</population>
          <units>percentage of total bacteria</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phylum Firmicutes at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1" spread="10.5"/>
                    <measurement group_id="O2" value="65.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phylum Firmicutes at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="13.3"/>
                    <measurement group_id="O2" value="70.1" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phylum Bacteroidetes at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="11.9"/>
                    <measurement group_id="O2" value="25.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phylum Bacteroidetes at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="13.5"/>
                    <measurement group_id="O2" value="22.6" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison was made to 2 weeks minus baseline changes in phylum Firmicutes abundance between groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>p&lt;0.05 was defined as significant</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.6</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison was made to 2 weeks minus baseline changes in phylum Bacteroidetes abundance between groups.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <p_value_desc>p&lt;0.05 was defined as significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Short-chain Fatty Acids (SCFAs) at 2 Weeks</title>
        <description>Change from baseline in total SCFAs including acetate, propionate, butyrate and valerate in response to mixed-spice intervention for 2 weeks. SCFAs were measured in dry fecal sample determined as micromole per gram of dry weight.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mixed Spices Intervention Group</title>
            <description>Healthy participants consumed 5 g of mixed spices daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Healthy participants consumed placebo capsules containing 5 g of maltodextrin daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Short-chain Fatty Acids (SCFAs) at 2 Weeks</title>
          <description>Change from baseline in total SCFAs including acetate, propionate, butyrate and valerate in response to mixed-spice intervention for 2 weeks. SCFAs were measured in dry fecal sample determined as micromole per gram of dry weight.</description>
          <units>micromole/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total SCFAs at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="595.6" spread="311.6"/>
                    <measurement group_id="O2" value="678.0" spread="328.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total SCFAs at week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="681.6" spread="333.2"/>
                    <measurement group_id="O2" value="733.7" spread="443.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparison was made to 2 weeks minus baseline in mixed spices intervention group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>86.0</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison was made to 2 weeks minus baseline in placebo group</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>55.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mixed Spices Intervention Group</title>
          <description>Healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
Mixed spice capsules contain 1 g cinnamon, 1.5 g oregano, 1.5 g ginger, 0.85g black pepper and 0.15g cayenne pepper for a total of 5.0 g.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Healthy participants consume placebo capsule containing 5 g of maltodextrin
Placebo capsules contain 5 g maltodextrin.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>stomach discomfort</sub_title>
                <description>Bloating, nausea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zhaoping Li, MD, PhD</name_or_title>
      <organization>UCLA Center for Human Nutrition</organization>
      <phone>310-206-1987</phone>
      <email>zli@medent.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

